Skip to main content

Pharmacology of Antidepressants and Mood Stabilizers

An overview of the pharmacology of various drug classes used to treat psychiatric disorders, including antidepressants (SSRIs, SNRIs, TCAs, MAOIs, NRIs) and mood stabilizers (Lithium, anticonvulsants). It details their mechanisms of action, sample drugs, adverse effects, and clinical uses.

Save this reading to your study set

Sign up free

The treatment of psychiatric disorders such as major depressive disorder (MDD), anxiety, and bipolar disorder relies heavily on the modulation of monoamine neurotransmitters. Specifically, the levels of serotonin (5-HT) and norepinephrine (NE) play a critical role in regulating mood, motivation, and reward. Understanding how various drug classes interact with these chemical messengers is essential for effective clinical management and the prevention of dangerous side effects.

The Monoamine Theory and the Therapeutic Delay

The "Monoamine Theory" of depression posits that a deficiency in the levels of norepinephrine and/or serotonin in the brain results in depressive symptoms. Conversely, excessive activity of these neurotransmitters is believed to contribute to the mania seen in bipolar disorder.

However, a significant challenge to this theory is the "therapeutic delay." While antidepressant drugs increase neurotransmitter levels almost immediately after administration, patients typically do not experience clinical improvement for 4 to 6 weeks.

The most widely accepted explanation for this delay involves the desensitization of presynaptic autoreceptors. Initially, the increase in neurotransmitter release triggers autoinhibitory feedback, which limits the effect. Over several weeks of chronic treatment, these presynaptic autoreceptors become desensitized, reducing the inhibitory feedback and allowing for enhanced postsynaptic receptor activity and a sustained therapeutic response.

Diagram illustrating neurotransmitter synthesis, release, and postsynaptic effect before and during acute treatment with TCA, SSRI, or SNRI.
Diagram illustrating neurotransmitter synthesis, release, and postsynaptic effect before and during acute treatment with TCA, SSRI, or SNRI.
Diagram illustrating the mechanism of action of antidepressants like TCA, SSRI, or SNRI on neurotransmitter signaling at a synapse.
Diagram illustrating the mechanism of action of antidepressants like TCA, SSRI, or SNRI on neurotransmitter signaling at a synapse.

Antidepressant Drug Classes

Pharmacological intervention is categorized by which neurotransmitter transporters or enzymes the drugs target.

Keep reading for free.

Create an account to finish this reading and make it part of your study routine.

Continue reading free

Already have an account? Log in

Updated

Study it your way.

Import this reading into your study set to get started with another study mode.

Make it your own.

Keep this reading in a new study set, or add it to one you already use.